OMGA / Omega Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial on September 26

CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pion more_horizontal

It seems to take a lot to impress those invested in Omega Therapeutics Inc. The shares fell after the biotech reported what on the face of it were p more_horizontal

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pio more_horizontal

CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pio more_horizontal

Omega Therapeutics, Inc. (OMGA) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compare more_horizontal

OMGA has an early stage program targeting various cancers using epigenetics. They are backed by a VC and have a decent cash runway. Though too early s more_horizontal

The mean of analysts' price targets for Omega Therapeutics, Inc. (OMGA) points to a 59.6% upside in the stock. While this highly sought-after metric h more_horizontal

The mean of analysts' price targets for Omega Therapeutics, Inc. (OMGA) points to a 48.2% upside in the stock. While this highly sought-after metric h more_horizontal